Search results
Results From The WOW.Com Content Network
Zolpidem, sold under the brand name Ambien among others, is a medication primarily used for the short-term treatment of sleeping problems. [11] [16] Guidelines recommend that it be used only after cognitive behavioral therapy for insomnia and after behavioral changes, such as sleep hygiene, have been tried.
Brotizolam [3] (marketed under brand name Lendormin) is a sedative-hypnotic [4] thienotriazolodiazepine [5] drug which is a benzodiazepine analog. [6] It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to other short-acting hypnotic benzodiazepines such as triazolam or midazolam. [7]
Intensive care unit patients who receive higher doses over longer periods, typically via IV drip, are more likely to experience such side effects. Additionally, the prolonged use of tranquilizers increases the risk of obsessive and compulsive disorder, where the person becomes unaware whether he has performed a scheduled activity or not, he may ...
Pouring powder analyzed as alprazolam (brand name: Xanax) and zolpidem (brand name: Ambien) in a woman’s drink at a Boca Raton restaurant’s bar cost a Palm Beach County neurologist his medical ...
The manufacturer of Ambien on Wednesday dismissed actress Roseanne Barr’s suggestion that the sleep aid was to blame for her racist and anti-Semitic tweets that led to the cancellation of her ...
One in 10 women take medication to fall or stay asleep, according the Centers for Disease Control and Prevention.Laura Cathcart Robbins, 58, was one of them when she became addicted to Ambien, the ...
Drug-induced amnesia is amnesia caused by drugs. Amnesia may be therapeutic for medical treatment or for medical procedures, or it may be a side-effect of a drug, such as alcohol, or certain medications for psychiatric disorders, such as benzodiazepines. [1]
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.